Valuation : Vivoryon Therapeutics N.V.

Market Cap 33.76M 39.33M 31.61M 28.94M 54.52M 3.76B 54.68M 374M 146M 1.89B 148M 144M 6.27B P/E 2026 *
-3x
P/E 2027 * -3.08x
Enterprise Value 38.08M 44.36M 35.65M 32.65M 61.5M 4.24B 61.67M 422M 165M 2.14B 167M 163M 7.07B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
82.01%
Yield 2026 *
-
Yield 2027 * -
1 week+1.33%
Current month-4.60%
1 month-2.56%
3 months-8.80%
6 months-19.72%
Current year-19.72%
1 week 1.1
Extreme 1.1
1.14
1 month 1.1
Extreme 1.1
1.25
Current year 1
Extreme 1
1.65
1 year 1
Extreme 1
1.84
3 years 0.41
Extreme 0.41
12.9
5 years 0.41
Extreme 0.41
22.58
10 years 0.41
Extreme 0.41
24.4
Manager TitleAgeSince
Chief Executive Officer 66 2023-08-13
Director of Finance/CFO - 2024-02-29
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 56 2006-12-31
Director/Board Member 66 2023-09-14
Director/Board Member 58 -
Date Insider Type Main position Quantity % Market Cap.
10/23/25 Free

Chief Operating Officer

20,000 0.0767%
10/23/25 Buy

Chief Executive Officer

135,000 0.5179%
10/23/25 Free 20,000 0.0767%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+1.33%-33.72%-90.48% 39.33M
+0.10%+0.44%+2.80%+24.32% 50.96B
+2.65%+4.45%+481.36%+567.32% 46.18B
-0.88%+0.90%+24.11%+87.74% 42.73B
+0.33%+2.47%+38.97%+19.80% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
-1.21%-0.17%+29.16%+135.38% 17.28B
-0.36%-2.14% - - 16.43B
+0.25%+0.25%+12.03%+30.68% 14.73B
+0.44%+1.70%+82.07%+47.92% 14.09B
Average -0.09%+0.38%+72.33%+97.13% 27.9B
Weighted average by Cap. +0.04%+0.54%+104.33%+141.79%

Financials

2026 *2027 *
Net sales - -
Net income -10.4M -12.12M -9.74M -8.92M -16.8M -1.16B -16.84M -115M -45.07M -583M -45.49M -44.51M -1.93B -10.4M -12.12M -9.74M -8.92M -16.8M -1.16B -16.84M -115M -45.07M -583M -45.49M -44.51M -1.93B
Net Debt 4.32M 5.03M 4.04M 3.7M 6.98M 481M 7M 47.89M 18.72M 242M 18.89M 18.49M 802M 13.03M 15.18M 12.2M 11.17M 21.04M 1.45B 21.1M 144M 56.47M 731M 56.99M 55.76M 2.42B
Logo Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. The Company leverages its in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Vivoryon Therapeutics N.V. has established a pipeline of orally available small molecule inhibitors for various indications including Alzheimer's disease, inflammatory and fibrotic disorders, including of the kidney, and cancer.
Employees
13
Date Price Change Volume
26-08-27 €1.140 0.00% 25,851
26-08-26 €1.140 +1.79% 5,979
26-08-25 €1.120 0.00% 24,408
26-08-24 €1.120 -2.18% 10,044
26-08-21 €1.145 +1.78% 15,845
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.140EUR
Average target price
6.850EUR
Spread / Average Target
+500.88%

Annual profits - Rate of surprise